PLX · XBRL financial data

Protalix BioTherapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PLX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	62,898	38,350	47,638	65,494	53,399	52,744
Cost of revenue	10,873	16,349	19,592	22,982	24,319	26,993
Research and development	38,167	29,734	29,349	17,093	12,970	19,569
Selling, general and administrative	11,148	12,729	11,711	14,959	12,193	11,682
Operating income (loss)	2,710	(20,462)	(13,014)	10,460	3,917	(5,500)
Income tax expense (benefit)	—	—	530	254	1,222	996
Net income (loss)	(6,523)	(27,582)	(14,927)	8,312	2,932	(6,604)
Earnings per share, basic USD per share	(0.22)	(0.62)	(0.31)	0.12	0.04	(0.08)
Earnings per share, diluted USD per share	(0.22)	(0.62)	(0.31)	0.09	0.04	(0.08)
Weighted average shares, basic thousands of shares	29,148	44,140	48,472	67,513	72,531	78,546
Weighted average shares, diluted thousands of shares	29,148	44,140	48,472	82,424	81,057	78,546

Fiscal years (PLX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	18,265	38,985	17,111	23,634	19,760	14,680
Accounts receivable	2,000	3,442	4,586	5,272	2,909	8,840
Inventory	13,082	17,954	16,804	19,045	21,243	25,729
Total current assets	55,723	61,666	44,880	69,932	60,078	66,673
Property and equipment, net	4,845	4,962	4,553	4,973	4,591	4,879
Right-of-use asset	5,567	4,960	5,087	5,909	5,430	7,700
Total assets	67,934	73,665	55,787	84,434	73,417	82,346
Accounts payable	13,926	16,433	12,271	19,550	—	—
Accrued liabilities	9,586	11,981	8,008	9,009	9,568	9,790
Total current liabilities	86,474	33,176	32,429	45,530	25,621	26,518
Lease liability, non-current	4,467	4,376	4,169	4,621	4,026	6,937
Total liabilities	94,971	79,701	66,427	50,865	30,206	34,116
Accumulated deficit	(347,352)	(374,934)	(389,861)	(381,549)	(378,393)	(384,997)
Total stockholders' equity	(27,037)	(6,036)	(10,640)	33,569	43,211	48,230
Total liabilities and equity	67,934	73,665	55,787	84,434	73,417	82,346
Common shares outstanding (cover page) thousands of shares	45,383	46,316	57,353	73,052	78,033	80,572

Fiscal years (PLX's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(6,523)	(27,582)	(14,927)	8,312	2,932	(6,604)
Stock-based compensation	3,126	2,375	2,085	3,448	3,253	2,297
Net cash from operating activities	(26,106)	(10,285)	(25,000)	(1,318)	8,674	(11,993)
Purchases of property and equipment	655	1,459	628	1,149	1,282	1,638
Net cash from investing activities	(19,952)	18,921	(5,035)	(16,711)	4,221	(2,366)
Proceeds from issuing common stock	4,867	8,575	8,236	23,954	3,626	6,812
Net cash from financing activities	46,467	12,078	8,238	24,666	(16,794)	9,326
Net change in cash	473	20,720	(21,874)	6,523	(3,874)	(5,080)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Protalix BioTherapeutics	27,420	19,896	(10,400)*	80.6M	2.6 quarters	Q2 FY26 10-QJun 30, 2026
Fate Therapeutics	32,429	2,082	(23,400)	119.8M	6.6 quarters	Q2 FY26 10-QJun 30, 2026
Caribou Biosciences	26,194	1,499	(22,787)*	107.2M	4.9 quarters	Q2 FY26 10-QJun 30, 2026
Protara Therapeutics	17,076	not reported	(15,389)*	59.1M	9.3 quarters	Q2 FY26 10-QJun 30, 2026
TuHURA Biosciences	996	not reported	(8,634)*	63.7M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Alector	59,915	3,320	(34,217)*	111.7M	5.1 quarters	Q2 FY26 10-QJun 30, 2026
Enanta Pharmaceuticals	33,419	14,359	(9,972)*	29.1M	19.0 quarters	Q3 FY26 10-QJun 30, 2026
Galectin Therapeutics	13,269	not reported	(2,439)*	100.8M	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Cartesian Therapeutics	147,606	0	(21,082)*	30.3M	7.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.